These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37801197)

  • 1. A multitask deep learning radiomics model for predicting the macrotrabecular-massive subtype and prognosis of hepatocellular carcinoma after hepatic arterial infusion chemotherapy.
    He X; Li K; Wei R; Zuo M; Yao W; Zheng Z; He X; Fu Y; Li C; An C; Liu W
    Radiol Med; 2023 Dec; 128(12):1508-1520. PubMed ID: 37801197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram.
    Xu Z; An C; Shi F; Ren H; Li Y; Chen S; Dou J; Wang Y; Yan S; Lu J; Chen H
    Eur Radiol; 2023 Dec; 33(12):9038-9051. PubMed ID: 37498380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-Energy CT Deep Learning Radiomics to Predict Macrotrabecular-Massive Hepatocellular Carcinoma.
    Li M; Fan Y; You H; Li C; Luo M; Zhou J; Li A; Zhang L; Yu X; Deng W; Zhou J; Zhang D; Zhang Z; Chen H; Xiao Y; Huang B; Wang J
    Radiology; 2023 Aug; 308(2):e230255. PubMed ID: 37606573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar Efficacy Between Atezolizumab Plus Bevacizumab
    Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
    In Vivo; 2024; 38(4):1854-1858. PubMed ID: 38936922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative prediction of macrotrabecular-massive hepatocellular carcinoma through dynamic contrast-enhanced magnetic resonance imaging-based radiomics.
    Zhang Y; He D; Liu J; Wei YG; Shi LL
    World J Gastroenterol; 2023 Apr; 29(13):2001-2014. PubMed ID: 37155523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gadoxetic acid-enhanced MRI of macrotrabecular-massive hepatocellular carcinoma and its prognostic implications.
    Rhee H; Cho ES; Nahm JH; Jang M; Chung YE; Baek SE; Lee S; Kim MJ; Park MS; Han DH; Choi JY; Park YN
    J Hepatol; 2021 Jan; 74(1):109-121. PubMed ID: 32818570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.
    Liu M; Shi J; Mou T; Wang Y; Wu Z; Shen A
    J Gastroenterol Hepatol; 2020 Aug; 35(8):1277-1287. PubMed ID: 32052876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of macrotrabecular-massive hepatocellular carcinoma by using MR-based models and their prognostic implications.
    Chai F; Ma Y; Feng C; Jia X; Cui J; Cheng J; Hong N; Wang Y
    Abdom Radiol (NY); 2024 Feb; 49(2):447-457. PubMed ID: 38042762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
    Ando E; Tanaka M; Yamashita F; Kuromatsu R; Yutani S; Fukumori K; Sumie S; Yano Y; Okuda K; Sata M
    Cancer; 2002 Aug; 95(3):588-95. PubMed ID: 12209752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of prognostic nomograms for large hepatocellular carcinoma after HAIC.
    Yao W; Wei R; Jia J; Li W; Zuo M; Zhuo S; Shi G; Wu P; An C
    Ther Adv Med Oncol; 2023; 15():17588359231163845. PubMed ID: 37113732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of serum AFP trajectories and hepatocellular carcinoma outcomes after hepatic arterial infusion chemotherapy: A longitudinal, multicenter study.
    An C; Wei R; Yao W; Han W; Li W; Shi G; Wu P
    Cancer Med; 2024 Jun; 13(11):e7319. PubMed ID: 38819606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH; Lee DS; Cho CW; Yun SS
    World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma.
    Feng Z; Li H; Liu Q; Duan J; Zhou W; Yu X; Chen Q; Liu Z; Wang W; Rong P
    Radiology; 2023 Apr; 307(1):e221291. PubMed ID: 36511807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
    Nagai H; Mukozu T; Ogino YU; Matsui D; Matsui T; Wakui N; Momiyama K; Igarashi Y; Sumino Y; Higai K
    Anticancer Res; 2015 Apr; 35(4):2269-77. PubMed ID: 25862889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiphase Liver MRI for Identifying the Macrotrabecular-Massive Subtype of Hepatocellular Carcinoma.
    Mulé S; Galletto Pregliasco A; Tenenhaus A; Kharrat R; Amaddeo G; Baranes L; Laurent A; Regnault H; Sommacale D; Djabbari M; Pigneur F; Tacher V; Kobeiter H; Calderaro J; Luciani A
    Radiology; 2020 Jun; 295(3):562-571. PubMed ID: 32228294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
    Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.